Danaher Corporation DHR is scheduled to release second-quarter 2023 results on Jul 25, before market open. The Zacks Consensus Estimate for the company’s second-quarter earnings has been revised ...
In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Danaher Corporation is one of them. Danaher Corporation (NYSE:DHR), a global leader in life sciences ...
I reiterate my 'Strong Buy' rating for Danaher, with a one-year price target of $310 per share, citing recovery in bioprocessing and market share gains in molecular testing. Danaher's bioprocessing ...
StockStory.org on MSN
Why Danaher (DHR) Stock Is Trading Up Today
What Happened? Shares of diversified science and technology company Danaher (NYSE:DHR) jumped 6.6% in the afternoon session after its subsidiary, Leica Biosystems, announced the launch of new ...
Danaher Corporation DHR stands to benefit from a strong performance of its Life Sciences segment owing to robust demand for bioprocessing products despite supply-chain constraints and raw material ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback